drugset / Trial / NCT03319810

Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease

NCT03319810

Phase 2 Completed 5 enrolled Sutter Health
NaSingle-groupOpen-labelTreatment

Summary

This is a proof of concept study to determine if changes in brain amyloid levels are evident three months after infusion of 0.4 g/kg of IVIG every 14 days x 5 infusions. Amyloid levels will be measured by Florbetapir PET and retinal scan.

Timeline

Start
2018-01-04
Primary completion
2018-07-19
Completion
2018-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 0.4 g/kg Intravenous